Abstract
Iron is essential for oxygen transport, energy metabolism, and immune regulation. Yet iron deficiency is the most common micronutrient disorder across all age groups, affecting nearly one quarter of the global population. Iron deficiency triggers nutritional immunity, a host defense mechanism that withholds and redistributes iron, contributing to increased morbidity and mortality. This review outlines normal iron physiology, distribution and absorption pathways and on the consequences of deficiency across body compartments, with particular attention to type 2-driven diseases. Beyond anemia, insufficient iron availability disrupts immune homeostasis by promoting type 2 inflammation, elevating IgE, and activating mast cells and eosinophils. Regulatory macrophages, the central hub of iron cycling, adopt an inflammatory, iron-sequestering state that reinforces malabsorption and redistribution. Epidemiology studies show higher iron-deficiency risk in allergic individuals; low maternal iron or early-life iron predisposes to eczema, wheeze, and asthma, while food-allergen elimination (notably cow's milk) further worsens anemia risk. Clinical evidence indicates that restoring iron status through diet, supplementation, or fortification lowers IgE levels, improves lung function, and alleviates symptoms of rhinitis, urticaria, and asthma. Iron may therefore represent a modifiable determinant of allergic disease development and severity. Integrating iron assessment and nutritional care into allergy management may reduce disease burden and slow the progression of allergic march.
| Original language | English |
|---|---|
| Journal | Allergy |
| DOIs | |
| Publication status | E-pub ahead of print - 6 Apr 2026 |
Bibliographical note
Publisher Copyright:© 2026 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Funding
Ioana Agache, Beatriz Cabanillas, Roberto Berni Canani, Pasquale Comberiati, Nikos Douladiris, Holger Garn, Karin Hufnagl, Ekaterina Khaleva, Gregorio Milani Paolo, Daniel Munblit, Diego G. Peroni, Frank Redegeld, Carmen Riggioni, Betty vanEsch, Emiliia Vassilopoulou have no conflicts of interest to declare related to the topic of this paper. Cristina Gomez‐Casado is co‐inventor of EP2894478, Gregorio P. Milani received grants from Angelini S.P.A. and Reckitt 457 Benckiser Healthcare S.P.A., and acted as advisor for scientific projects funded by Angelini S.P.A; Liam O'Mahony reports research grants from Chiesi, Reckitt and Fonterra, and participation in speaker bureau for Nestle, Yakult, Reckitt and Abbott. Peter Smith declares honoraria, speaker and advisory board fees from GSK, Sanofi and Viatris. Investigator Initiated funding from Sanofi, GSK and Hyloris. Research Funding From NH&MRC and Stafford Fox Foundations. Carina Venter has provided consultancy/educational lectures to Danone, Reckitt, Abbott, Nestle Nutrition Institute, Franziska Roth‐Walter is lead inventor of EP2894478, has served as an investigator, speaker, and/or advisor for Biomedical Int R&D, Allergy Therapeutics and Bencard and is founder and shareholder of ViaLym FlexCo. This Position Paper was supported by the European Academy of Allergy and Clinical Immunology (EAACI) under the EAACI Taskforce Micronutrients and the Working Group Immunomodulation and Nutrition, 40328, 2023–2025.
| Funders | Funder number |
|---|---|
| Sanofi | |
| European Academy of Allergy and Clinical Immunology | |
| Chiesi, Reckitt and Fonterra | |
| GSK | |
| EAACI Taskforce Micronutrients | 40328 |
Keywords
- HIF1 alpha
- HIF2 alpha
- allergy
- anemia of chronic inflammation
- atopic diseases
- atopy
- hepcidin
- inflammation
- iron-deficiency
- type 2
Fingerprint
Dive into the research topics of 'Iron Physiology and Its Impact on Atopic Diseases: An EAACI Taskforce Report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver